Eli Lilly (LLY)

The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.

The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless surge in artificial intelligence (AI) innovation, the market has recently succumbed to heightened volatility. Investor sentiment is a delicate balance

The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year.

Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement of disappointing results from its highly anticipated late-stage clinical trials for an Alzheimer's disease drug. The trials, which tested an oral formulation

Eli Lilly fell while Biogen jumped.

Investing in an S&P 500 index fund can be a great way to build long-term wealth.

Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability.

After a bruising week, Wall Street regained its footing on Friday as rate-cut hopes resurfaced and fears around the AI sell-off eased, if only slightly. Solid PMI data and improving inflation expectations helped stabilize sentiment.

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst performers in the branded pharmaceuticals industry.

These Magnificent Seven players are well-positioned to benefit in the AI boom.

Who says you have to choose between the two?

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

November is a great month to be thankful for opportunities to invest in these fantastic companies.

Eli Lilly stock has already rallied 70% in less than four months.

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.

Eli Lilly hit a $1 trillion valuation for the first time, becoming the only healthcare company to reach the milestone as demand for its weight-loss drugs continues to surge.

Eli Lilly and Co (NYSE:LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access.

Concerns are mounting across financial markets regarding a potential "AI bubble," as sky-high valuations for technology companies, particularly those focused on artificial intelligence, trigger comparisons to past speculative frenzies. This apprehension is influencing market sentiment, leading to significant volatility and a re-evaluation of investment strategies. While the transformative power of AI is undeniable, the sustainability [...]

Eli Lilly became the first health care company to top $1 trillion in market capitalization on Friday.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and the best and worst performers in the branded pharmaceuticals industry.

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain...